ICON plc is a healthcare intelligence and clinical research organization (CRO) that provides outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company offers clinical development, functional outsourcing, and laboratory services. Its clinical development services include all phases of development (Phases I-IV), pre and post-approval, data solutions, and site and patient access services. Laboratory services provide testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice (GMP), and central laboratory services. ICON concentrates on therapeutic areas such as oncology, central nervous system, vaccines, cell and gene therapies, cardiovascular, gastrointestinal, ophthalmology, rare and orphan diseases, respiratory, biosimilars, autoimmune diseases, internal medicine and immunology, women’s health therapeutics, and paediatrics.

ICON delivers differentiated, decentralised, and hybrid trial solutions through a suite of capabilities consisting of mobile health, commercial connected health platforms, real-world data and information solutions, a global site network, home health services, and wearables expertise. The company’s consulting and advisory services include novel statistical methods and adaptive trials, dose optimisation strategies, due diligence and asset valuation, non-clinical and preclinical development, regulatory intelligence, regulatory services in early development, clinical trial regulatory support, strategic regulatory services, chemistry, manufacturing, and controls (CMC), health economics and outcome research; market research and analytics, and creative design and digital services.